Correction: Natalizumab stabilizes physical, cognitive, MRI, and OCT markers of disease activity: A prospective, non-randomized pilot study (PLoS ONE (2017) 12:4 (e0173299) DOI: 10.1371/journal.pone.0173299)

Garrick D. Talmage, Oscar J.M. Coppes, Adil Javed, Jacqueline Bernard

Research output: Contribution to journalComment/debatepeer-review

Abstract

There are errors in the author affiliations. The affiliations should appear as shown here: Garrick D. Talmage 1 , Oscar J. M. Coppes 2 , Adil Javed 3 , Jacqueline Bernard 4 1 Department of Otolaryngology, University of Colorado, Aurora, Colorado, United States of America, 2 Department of Anesthesia, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States of America, 3 Department of Neurology, The University of Chicago, Chicago, Illinois, United States of America, 4 Department of Neurology, Oregon Health Science University, Portland, Oregon, United States of America.

Original languageEnglish (US)
Article numbere0178338
JournalPloS one
Volume12
Issue number5
DOIs
StatePublished - May 2017

ASJC Scopus subject areas

  • General Biochemistry, Genetics and Molecular Biology
  • General Agricultural and Biological Sciences
  • General

Fingerprint

Dive into the research topics of 'Correction: Natalizumab stabilizes physical, cognitive, MRI, and OCT markers of disease activity: A prospective, non-randomized pilot study (PLoS ONE (2017) 12:4 (e0173299) DOI: 10.1371/journal.pone.0173299)'. Together they form a unique fingerprint.

Cite this